RBC Capital analyst Gregory Renza maintained a Buy rating on Morphic Holding (NASDAQ:MORF) Inc on Thursday, setting a price target of $82, which is approximately 48.01% above the present share price of $55.4.
Renza expects Morphic Holding Inc to post earnings per share (EPS) of -$0.57 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Morphic Holding, with an average price target of $100.5.
The analysts price targets range from a high of $115 to a low of $82.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $5.9 million and a net profit of -$17.98 million. The company's market cap is $1.99 billion.
According to TipRanks.com, RBC Capital analyst Gregory Renza is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 6.9% and a 39.29% success rate.
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.